Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06682806 · ClinicalTrials.gov registry record · Phase 2
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
A Phase 2 study, sponsored by Prelude Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT06682806 is a Phase 2 study that was terminated before completion, run by Prelude Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT06682806, a Phase 2 study, was terminated before completion, sponsored by Prelude Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with advanced, recurrent or metastatic solid tumors with a SMARCA4 mutation.
Interventions
- DRUG pembrolizumab
- DRUG PRT3789
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-06-03 |
| Est. Completion | 2026-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06682806
The ClinicalTrials.gov registry entry for NCT06682806 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prelude Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT06682806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06682806 about?
NCT06682806 is a clinical study titled "A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation". This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with advanced, recurrent or metastatic solid tumors with a SMARCA4 mutation.
What is the current status of trial NCT06682806?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2025-06-03. Estimated completion is 2026-01-23.
What interventions are being tested in trial NCT06682806?
The interventions under investigation include: pembrolizumab (DRUG), PRT3789 (DRUG).
Who is sponsoring clinical trial NCT06682806?
This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.